Cerebrospinal fluid biomarker candidates of schizophrenia: Where do we stand?

European Archives of Psychiatry and Clinical Neuroscience

Volumn 262, Issue 5, 2012, Pages 375-391

  Connemann, Bernhard J ^a   Wolf, Robert C ^b   Tumani, Hayrettin ^a   Brettschneider, Johannes ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blood CSF barrier; Cerebrospinal fluid; Cytokines; Proteomics; Schizophrenia

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID; GLUCOSE; HALOPERIDOL; IMMUNOGLOBULIN; LACTIC ACID; MONOAMINE; NERVE GROWTH FACTOR;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; HUMAN; METABOLITE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

BIOGENIC MONOAMINES; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; CANNABINOIDS; CELL COUNT; CYTOKINES; DATABASES, FACTUAL; FATTY ACIDS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; HYDROLASES; IMMUNOGLOBULINS; LACTIC ACID; MODELS, BIOLOGICAL; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; PROTEOMICS; SCHIZOPHRENIA;

EID: 84865038082     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-011-0280-9     Document Type: Article

References (162)

1. Albrecht P, Torrey EF, Boone E, Hicks JT, Daniel N (1980) Raised cytomegalovirus-antibody level in cerebrospinal fluid of schizophrenic patients. Lancet 2:769-772 (Pubitemid 10004104)
2. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, Black IB (2003) Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity. J Neurosci 23:10800-10808 (Pubitemid 37499686)
3. Amminger GP, McGorry PD, Berger GE, Wade D, Yung AR, Phillips LJ, Harrigan SM, Francey SM, Yolken RH (2007) Antibodies to infectious agents in individuals at ultra-high risk for psychosis. Biol Psychiatry 61:1215-1217
4. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146-154
5. Araque A, Parpura V, Sanzgiri RP, Haydon PG (1999) Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci 22:208-215 (Pubitemid 29202082)
6. Aurell A, Rosengren LE, Karlsson B, Olsson JE, Zbornikova V, Haglid KG (1991) Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 22:1254-1258
7. Axelsson R, Martensson E, Alling C (1982) Impairment of the blood-brain barrier as an aetiological factor in paranoid psychosis. Br J Psychiatry 141:273-281 (Pubitemid 12052487)
8. Barak V, Barak Y, Levine J, Nisman B, Roisman I (1995) Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients. J Basic Clin Physiol Pharmacol 6:61-69
9. Bauer K, Kornhuber J (1987) Blood-cerebrospinal fluid barrier in schizophrenic patients. Eur Arch Psychiatry Neurol Sci 236:257-259 (Pubitemid 17130316)
10. Beaudry P, Cohen P, Brandel JP, Delasnerie-Laupretre N, Richard S, Launay JM, Laplanche JL (1999) 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 10:40-46 (Pubitemid 28567041)
11. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG (2010) Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 44:321-330
12. Ben-Shachar D, Livne E, Spanier I, Leenders KL, Youdim MB (1994) Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. J Neurochem 62:1112-1118
13. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H, Agam G (2007) A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 90:41-51 (Pubitemid 46177566)
14. Bianchi R, Giambanco I, Donato R (1993) S-100 protein, but not calmodulin, binds to the glial fibrillary acidic protein and inhibits its polymerization in a Ca(2 +)-dependent manner. J Biol Chem 268:12669-12674 (Pubitemid 23182431)
15. Blennow K, Fredman P, Wallin A, Gottfries CG, Karlsson I, Langstrom G, Skoog I, Svennerholm L, Wikkelso C (1993) Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 33:129-133 (Pubitemid 23100537)
16. Blennow K, Fredman P, Wallin A, Gottfries CG, Langstrom G, Svennerholm L (1993) Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur Neurol 33:126-128 (Pubitemid 23100536)
17. Blennow K, Fredman P, Wallin A, Gottfries CG, Skoog I, Wikkelso C, Svennerholm L (1993) Protein analysis in cerebrospinal fluid. III. Relation to blood-cerebrospinal fluid barrier function for formulas for quantitative determination of intrathecal IgG production. Eur Neurol 33:134-142 (Pubitemid 23100538)
18. Blennow K, Vanmechelen E, Hampel H (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24:87-97 (Pubitemid 34066679)
19. Bock E (1978) Immunoglobulins, prealbumin, transferrin, albumin, and alpha2-macroglobulin in cerebrospinal fluid and serum in schizophrenic patients. Birth Defects Orig Artic Ser 14:283-295 (Pubitemid 9076064)
20. Brettschneider J, Claus A, Kassubek J, Tumani H (2005) Isolated blood-cerebrospinal fluid barrier dysfunction: prevalence and associated diseases. J Neurol 252:1067-1073 (Pubitemid 41355837)
21. Brown KW, Kynoch PA, Thompson RJ (1980) Immunoreactive nervous system of specific enolase (14-3-2 protein) in human serum and cerebrospinal fluid. Clin Chim Acta 101:257-264 (Pubitemid 10168619)
22. Bruetsch WL, Bahr MA, Skobba JS, Dieter WJ (1942) The group of dementia praecox patients with an increase of the protein content of the cerebrospinal fluid. J Nerv Ment Dis 95:669-679
23. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S (2007) Brain derived neurotropic factor in first-episode psychosis. Schizophr Res 91:1-5
24. Buttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W (1997) S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 28:1961-1965 (Pubitemid 27459004)
25. Chapman ER (2002) Synaptotagmin: a Ca(2 +) sensor that triggers exocytosis? Natl Rev Mol Cell Biol 3:498-508
26. Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang XY (2009) Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 207:375-380
27. Corradini I, Verderio C, Sala M, Wilson MC, Matteoli M (2009) SNAP-25 in neuropsychiatric disorders. Ann N Y Acad Sci 1152:93-99
28. Crols R, Saerens J, Noppe M, Lowenthal A (1986) Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome. J Neurol 233:157-160 (Pubitemid 16114595)
29. Delisi LE, Weinberger DR, Potkin S, Neckers LM, Shiling DJ, Wyatt RJ (1981) Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients. Br J Psychiatry 139:513-518 (Pubitemid 12241778)
30. Dencker SJ, Zethraeus S (1961) Sex differences in total protein content of cerebrospinal fluid. Acta Psychiatr Scand 36:76-82
31. Do KQ, Lauer CJ, Schreiber W, Zollinger M, Gutteck-Amsler U, Cuenod M, Holsboer F (1995) gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 65:2652-2662 (Pubitemid 3002922)
32. Durany N, Michel T, Zochling R, Boissl KW, Cruz-Sanchez FF, Riederer P, Thome J (2001) Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res 52:79-86 (Pubitemid 32947050)
33. Egan MF, el-Mallakh RS, Suddath RL, Lohr JB, Bracha HS, Wyatt RJ (1992) Cerebrospinal fluid and serum levels of neuron-specific enolase in patients with schizophrenia. Psychiatry Res 43:187-195
34. el-Mallakh RS, Suddath RL, Wyatt RJ (1993) Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 17:383-391 (Pubitemid 23096382)
35. Fassbender K, Schmidt R, Schreiner A, Fatar M, Muhlhauser F, Daffertshofer M, Hennerici M (1997) Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke. J Neurol Sci 148:101-105 (Pubitemid 27149530)
36. Fernandez-Espejo E, Viveros MP, Nunez L, Ellenbroek BA, Rodriguez de Fonseca F (2009) Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology (Berl) 206:531-549
37. Fuchs SA, De Barse MM, Scheepers FE, Cahn W, Dorland L, der Velden MG, Klomp LW, Berger R, Kahn RS, de Koning TJ (2008) Cerebrospinal fluid d-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients. Eur Neuropsychopharmacol 18:333-338
38. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108-2114 (Pubitemid 39486563)
39. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindstrom LH, Iyo M (2005) Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 29:767-769 (Pubitemid 40897791)
40. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M (2003) Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60:572-576 (Pubitemid 36682314)
41. Hayakawa T, Ushio Y, Mori T, Arita N, Yoshimine T, Maeda Y, Shimizu K, Myoga A (1979) Levels in stroke patients of CSF astroprotein, an astrocyte-specific cerebroprotein. Stroke 10:685-689 (Pubitemid 10203462)
42. Hodel A (1998) Snap-25. Int J Biochem Cell Biol 30:1069-1073 (Pubitemid 28485750)
43. Hoerster SA Jr, Hillman FA, Bohls SW, Lara FY, Thurman N (1963) Cerebrospinal fluid in mental diseases (a study using paper electrophoresis). Dis Nerv Syst 24:357-360
44. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Nicholson JK, Bahn S (2006) Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 3:e327
45. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Reed B, Bahn S (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3:e428 ChemPort
46. Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW, Gross S, Schreiber D, Ruhrmann S, Schultze-Lutter F, Klosterkotter J, Holmes E, Bahn S (2007) CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2:e756
47. Hunnerkopf R, Grassl J, Thome J (2007) Proteomics: biomarker research in psychiatry. Fortschr Neurol Psychiatry 75:579-586 (Pubitemid 350082984)
48. Hunter R, Jones M, Malleson A (1969) Abnormal cerebrospinal fluid protein and gammaglobulin levels in 256 patients admitted to a psychiatric unit. J Neurol Sci 9:11-38
49. Hur EM, Zhou FQ (2010) GSK3 signalling in neural development. Nat Rev Neurosci 11:539-551
50. Issa G, Wilson C, Terry AV Jr, Pillai A (2010) An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 39:327-333
51. Jablensky A (1997) The 100-year epidemiology of schizophrenia. Schizophr Res 28:111-125 (Pubitemid 28055660)
52. Jacobsen LK, Frazier JA, Malhotra AK, Karoum F, McKenna K, Gordon CT, Hamburger SD, Lenane MC, Pickar D, Potter WZ, Rapoport JL (1997) Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Am J Psychiatry 154:69-74 (Pubitemid 27020195)
53. Jesse S, Steinacker P, Cepek L, von Arnim CA, Tumani H, Lehnert S, Kretzschmar HA, Baier M, Otto M (2009) Glial fibrillary acidic protein and protein S-100B: different concentration pattern of glial proteins in cerebrospinal fluid of patients with Alzheimer's disease and Creutzfeldt-Jakob disease. J Alzheimers Dis 17:541-551
54. Jessen KR, Mirsky R (1980) Glial cells in the enteric nervous system contain glial fibrillary acidic protein. Nature 286:736-737 (Pubitemid 11247290)
55. Jethwa PH, Ebling FJ (2008) Role of VGF-derived peptides in the control of food intake, body weight and reproduction. Neuroendocrinology 88:80-87
56. Jiang L, Lindpaintner K, Li HF, Gu NF, Langen H, He L, Fountoulakis M (2003) Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 25:49-57 (Pubitemid 36930212)
57. Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS (2010) Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr Res 119:47-51
58. Joy CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 3:CD001257
59. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993) Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 50:599-605 (Pubitemid 23229268)
60. Kale A, Joshi S, Pillai A, Naphade N, Raju M, Nasrallah H, Mahadik SP (2009) Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naive psychotic patients. Schizophr Res 115:209-214
61. Katila H, Hurme M, Wahlbeck K, Appelberg B, Rimon R (1994) Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. Neuropsychobiology 30:20-23 (Pubitemid 24211368)
62. Kirch DG, Kaufmann CA, Papadopoulos NM, Martin B, Weinberger DR (1985) Abnormal cerebrospinal fluid protein indices in schizophrenia. Biol Psychiatry 20:1039-1046 (Pubitemid 16077294)
63. Kirch DG, Alexander RC, Suddath RL, Papadopoulos NM, Kaufmann CA, Daniel DG, Wyatt RJ (1992) Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J Neural Transm Gen Sect 89:219-232
64. Koethe D, Giuffrida A, Schreiber D, Hellmich M, Schultze-Lutter F, Ruhrmann S, Klosterkotter J, Piomelli D, Leweke FM (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry 194:371-372
65. Koros E, Dorner-Ciossek C (2007) The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect 20:437-445 (Pubitemid 350232812)
66. Kozlovsky N, Belmaker RH, Agam G (2001) Low GSK-3 activity in frontal cortex of schizophrenic patients. Schizophr Res 52:101-105 (Pubitemid 32947052)
67. Kozlovsky N, Belmaker RH, Agam G (2000) Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry 157:831-833 (Pubitemid 30249669)
68. Kozlovsky N, Nadri C, Agam G (2005) Low GSK-3beta in schizophrenia as a consequence of neurodevelopmental insult. Eur Neuropsychopharmacol 15:1-11 (Pubitemid 39585137)
69. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G (2004) GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm 111:1093-1098 (Pubitemid 39037129)
70. Kranaster L, Koethe D, Hoyer C, Meyer-Lindenberg A, Leweke FM (2011) Cerebrospinal fluid diagnostics in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci 261:529-530
71. Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatr 157:683-694 (Pubitemid 30249643)
72. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, Fonseca M, Hauck S, Souza DO (2001) Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatry Res 35:11-14 (Pubitemid 32233165)
73. Leweke FM, Gerth CW, Koethe D, Klosterkotter J, Ruslanova I, Krivogorsky B, Torrey EF, Yolken RH (2004) Antibodies to infectious agents in individuals with recent onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 254:4-8 (Pubitemid 39310542)
74. Leweke FM, Giuffrida A, Koethe D, Schreiber D, Nolden BM, Kranaster L, Neatby MA, Schneider M, Gerth CW, Hellmich M, Klosterkotter J, Piomelli D (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 94:29-36 (Pubitemid 47031599)
75. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665-1669 (Pubitemid 29354290)
76. Li S, Wu H, Guo H, Zhao Z (2006) Neuron-specific Enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia. J Huazhong Univ Sci Technolog Med Sci 26:228-230
77. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH (1993) Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 150:1408-1410 (Pubitemid 23259579)
78. Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, Weng YZ, Yang TS (2007) Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatry Res 41:36-42 (Pubitemid 44708208)
79. Liu J, Shi Y, Tang J, Guo T, Li X, Yang Y, Chen Q, Zhao X, He G, Feng G, Gu N, Zhu S, Liu H, He L (2005) SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328:335-341 (Pubitemid 40164673)
80. Manabe T (2002) Does BDNF have pre- or postsynaptic targets? Science 295:1651-1653. (Pubitemid 34202886)
81. Martins-de-Souza D (2010) Is the word 'biomarker' being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260:561-562
82. Martins-de-Souza D, Maccarrone G, Wobrock T, Zerr I, Gormanns P, Reckow S, Falkai P, Schmitt A, Turck CW (2010) Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J Psychiatry Res 44:1176-1189
83. Martins-De-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, Falkai P, Turck CW (2010) Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 11:719-728
84. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, Yao J, Peters JL (1995) Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152:1291-1297
85. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D (2004) A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med 2:13
86. Miller C, Kirchmair R, Troger J, Saria A, Fleischhacker WW, Fischer-Colbrie R, Benzer A, Winkler H (1996) CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 39:911-918
87. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominiczak A, Ehrich JH, Fliser D, Girolami M, Hermjakob H, Hochstrasser D, Jankowski J, Julian BA, Kolch W, Massy ZA, Neusuess C, Novak J, Peter K, Rossing K, Schanstra J, Semmes OJ, Theodorescu D, Thongboonkerd V, Weissinger EM, Van Eyk JE, Yamamoto T (2007) Clinical proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 1:148-156
88. Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80:575-577
89. Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M (2005) Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19:164-170 (Pubitemid 40868045)
90. Müller N, Ackenheil M (1995) Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 14:223-228
91. Muller DJ, Klempan TA, De Luca V, Sicard T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA, Honer WG, Kennedy JL (2005) The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 379:81-89
92. Musil R, Spellmann I, Riedel M, Dehning S, Douhet A, Maino K, Zill P, Muller N, Moller HJ, Bondy B (2008) SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatry Res 42:963-970
93. Mustafa AK, Kumar M, Selvakumar B, Ho GP, Ehmsen JT, Barrow RK, Amzel LM, Snyder SH (2007) Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of d-serine formation. Proc Natl Acad Sci USA 104:2950-2955 (Pubitemid 46327984)
94. Nadri C, Dean B, Scarr E, Agam G (2004) GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res 71:377-382 (Pubitemid 39330516)
95. Nadri C, Kozlovsky N, Agam G, Bersudsky Y (2002) GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res 112:51-57
96. Niebuhr DW, Millikan AM, Cowan DN, Yolken R, Li Y, Weber NS (2008) Selected infectious agents and risk of schizophrenia among U.S. military personnel. Am J Psychiatry 165:99-106 (Pubitemid 351704558)
97. Niebuhr DW, Millikan AM, Yolken R, Li Y, Weber NS (2008) Results from a hypothesis generating case-control study: herpes family viruses and schizophrenia among military personnel. Schizophr Bull 34:1182-1188
98. Nikkila HV, Muller K, Ahokas A, Miettinen K, Rimon R, Andersson LC (1999) Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry 156:1725-1729 (Pubitemid 29517564)
99. Nikkila HV, Müller K, Ahokas A, Rimon R, Andersson LC (2001) Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res 49:99-105 (Pubitemid 32434317)
100. Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, Kida S, Shibata N, Suzuki T, Arai H (2008) Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 32:1905-1912
101. Otto M, Wiltfang J, Tumani H, Zerr I, Lantsch M, Kornhuber J, Weber T, Kretzschmar HA, Poser S (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225:210-212 (Pubitemid 27191632)
102. Oxenstierna G, Bergstrand G, Bjerkenstedt L, Sedvall G, Wik G (1984) Evidence of disturbed CSF circulation and brain atrophy in cases of schizophrenic psychosis. Br J Psychiatry 144:654-661 (Pubitemid 14109669)
103. Oxenstierna G, Bergstrand G, Edman G, Flyckt L, Nyback H, Sedvall G (1996) Increased frequency of aberrant CSF circulation in schizophrenic patients compared to healthy volunteers. Eur Psychiatry 11:16-20 (Pubitemid 26069830)
104. Pennington K, Cotter D, Dunn MJ (2005) The role of proteomics in investigating psychiatric disorders. Br J Psychiatry 187:4-6 (Pubitemid 41002506)
105. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ (2004) An ELISA for glial fibrillary acidic protein. J Immunol Methods 287:169-177 (Pubitemid 38510218)
106. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, Mahadik SP (2010) Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol 13:535-539
107. Puri BK (2010) Progressive structural brain changes in schizophrenia. Expert Rev Neurother 10:33-42
108. Raedler TJ, Wiedemann K (2006) CSF-studies in neuropsychiatric disorders. Neuro Endocrinol Lett 27:297-305 (Pubitemid 44390063)
109. Rais M, van Haren NE, Cahn W, Schnack HG, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS (2010) Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. Eur Neuropsychopharmacol 20:855-865
110. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM (1997) CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 25:123-129 (Pubitemid 27245134)
111. Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173-186 (Pubitemid 32728347)
112. Reiber H, Felgenhauer K (1987) Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 163:319-328 (Pubitemid 17050086)
113. Reichardt LF (2003) Neurobiology: signals that make waves. Nature 426:25-26 (Pubitemid 37432526)
114. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, Gournellis R, Lykouras L (2008) Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1308-1311
115. Roos KL (2003) Lumbar puncture. Semin Neurol 23:105-114 (Pubitemid 36857715)
116. Rose CR, Blum R, Pichler B, Lepier A, Kafitz KW, Konnerth A (2003) Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. Nature 426:74-78 (Pubitemid 37432543)
117. Rosengren LE, Ahlsen G, Belfrage M, Gillberg C, Haglid KG, Hamberger A (1992) A sensitive ELISA for glial fibrillary acidic protein: application in CSF of children. J Neurosci Methods 44:113-119
118. Rosenling T, Slim CL, Christin C, Coulier L, Shi S, Stoop MP, Bosman J, Suits F, Horvatovich PL, Stockhofe-Zurwieden N, Vreeken R, Hankemeier T, van Gool AJ, Luider TM, Bischoff R (2009) The effect of preanalytical factors on stability of the proteome and selected metabolites in cerebrospinal fluid (CSF). J Proteome Res 8:5511-5522
119. Rothermundt M, Ahn JN, Jorgens S (2009) S100B in schizophrenia: an update. Gen Physiol Biophys 28 Spec No Focus:F76-F81
120. Rothermundt M, Falkai P, Ponath G, Abel S, Burkle H, Diedrich M, Hetzel G, Peters M, Siegmund A, Pedersen A, Maier W, Schramm J, Suslow T, Ohrmann P, Arolt V (2004) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9:897-899 (Pubitemid 39381953)
121. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H (2001) Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6:445-449 (Pubitemid 32566096)
122. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29:1004-1011 (Pubitemid 38526800)
123. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, Sarandol E (2007) Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatrty 31:1164-1169 (Pubitemid 47081301)
124. Scheepers FE, Gispen-de Wied CC, Westenberg HG, Kahn RS (2001) The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology 25:468-475 (Pubitemid 32830951)
125. Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P (2005) Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 80:305-313 (Pubitemid 41713656)
126. Schönknecht P, Hempel A, Hunt A, Seidl U, Volkmann M, Pantel J, Schröder J (2003) Cerebrospinal fluid tau protein levels in schizophrenia. Eur Arch Psychiatry Clin Neurosci 253:100-102 (Pubitemid 37205485)
127. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 167:66-72
128. Schuller EA, Benabdallah S, Sagar HJ, Reboul JA, Tompe LC (1987) IgG synthesis within the central nervous system. Comparison of three formulas. Arch Neurol 44:600-604 (Pubitemid 17073187)
129. Schwarz E, Bahn S (2008) Biomarker discovery in psychiatric disorders. Electrophoresis 29:2884-2890 (Pubitemid 352006122)
130. Schwarz E, Bahn S (2008) Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Rev Mol Diagn 8:209-216 (Pubitemid 351469440)
131. Schwarz E, Bahn S (2008) The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol 153(Suppl 1):S133-S136 (Pubitemid 351341011)
132. Schwarz MJ, Ackenheil M, Riedel M, Muller N (1998) Blood-cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia. Neurosci Lett 253:201-203 (Pubitemid 28442598)
133. Seehusen DA, Reeves MM, Fomin DA (2003) Cerebrospinal fluid analysis. Am Fam Physician 68:1103-1108 (Pubitemid 37173831)
134. Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 45:17-25 (Pubitemid 29049200)
135. Selemon LD, Mrzljak J, Kleinman JE, Herman MM, Goldman-Rakic PS (2003) Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Arch Gen Psychiatry 60:69-77 (Pubitemid 36070867)
136. Sokol DK, O'Brien RS, Wagenknecht DR, Rao T, McIntyre JA (2007) Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol 190:151-156 (Pubitemid 47625611)
137. Southwell BR, Duan W, Alcorn D, Brack C, Richardson SJ, Kohrle J, Schreiber G (1993) Thyroxine transport to the brain: role of protein synthesis by the choroid plexus. Endocrinology 133:2116-2126 (Pubitemid 23324717)
138. Spellmann I, Muller N, Musil R, Zill P, Douhet A, Dehning S, Cerovecki A, Bondy B, Moller HJ, Riedel M (2008) Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 258:335-344
139. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT (2006) Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 77:1284-1287 (Pubitemid 44654765)
140. Sugerman HJ, DeMaria EJ, Felton WL 3rd, Nakatsuka M, Sismanis A (1997) Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 49:507-511 (Pubitemid 27368891)
141. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Johnson MH, Krasulova E, Kuhle J, Magnone MC, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Giovannoni G, Hemmer B, Tumani H, Deisenhammer F (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914-1922
142. Thakker-Varia S, Alder J (2009) Neuropeptides in depression: role of VGF. Behav Brain Res 197:262-278
143. Thompson PM, Kelley M, Yao J, Tsai G, van Kammen DP (2003) Elevated cerebrospinal fluid SNAP-25 in schizophrenia. Biol Psychiatry 53:1132-1137 (Pubitemid 36695088)
144. Thompson PM, Rosenberger C, Qualls C (1999) CSF SNAP-25 in schizophrenia
145. Toorey EF, Peterson MR, Brannon WL, Carpenter WT, Post RM, Van Kammen DP (1978) Immunoglobulins and viral antibodies in psychiatric patients. Br J Psychiatry 132:342-348 (Pubitemid 8312590)
146. Torrey EF, Albrecht P, Behr DE (1985) Permeability of the blood-brain barrier in psychiatric patients. Am J Psychiatry 142:657-658
147. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J (2008) Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Rev Mol Diagn 8:479-494 (Pubitemid 351962092)
148. Van Eldik LJ, Wainwright MS (2003) The Janus face of glial-derived S100B: beneficial and detrimental functions in the brain. Restor Neurol Neurosci 21:97-108 (Pubitemid 37330251)
149. van Haren NE, Schnack HG, Cahn W, van den Heuvel MP, Lepage C, Collins L, Evans AC, Hulshoff Pol HE, Kahn RS (2011) Changes in cortical thickness during the course of illness in schizophrenia. Arch Gen Psychiatry 68:871-880
150. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK (1999) Elevated interleukin-6 in schizophrenia. Psychiatry Res 87:129-136 (Pubitemid 29494972)
151. Vasic N, Wolf RC (2006) How early is it possible to detect and to treat schizophrenia? Nervenheilkunde 25:351-358 (Pubitemid 44713311)
152. Verheecke P (1975) On the tau-protein in cerebrospinal fluid. J Neurol Sci 26:277-281
153. Verrall L, Walker M, Rawlings N, Benzel I, Kew JN, Harrison PJ, Burnet PW (2007) d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia. Eur J Neurosci 26:1657-1669 (Pubitemid 47416520)
154. Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, Arolt V, Kirchner H (1999) Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45:1508-1511 (Pubitemid 29457564)
155. Wilson RI, Nicoll RA (2002) Endocannabinoid signaling in the brain. Science 296:678-682
156. Wunderlich MT, Lins H, Skalej M, Wallesch CW, Goertler M (2006) Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 108:558-563 (Pubitemid 44189097)
157. Yolken R (2004) Viruses and schizophrenia: a focus on herpes simplex virus. Herpes 11(Suppl 2):83A-88A
158. Yolken RH, Torrey EF (2008) Are some cases of psychosis caused by microbial agents? A review of the evidence. Mol Psychiatry 13:470-479 (Pubitemid 351556038)
159. Young G, Conquer J (2005) Omega-3 fatty acids and neuropsychiatric disorders. Reprod Nutr Dev 45:1-28 (Pubitemid 40528530)
160. Yuan J, Yankner BA (2000) Apoptosis in the nervous system. Nature 407:802-809
161. Zimmer DB, Cornwall EH, Landar A, Song W (1995) The S100 protein family: history, function, and expression. Brain Res Bull 37:417-429
162. Zimmer DB, Van Eldik LJ (1986) Identification of a molecular target for the calcium-modulated protein S100. Fructose-1, 6-bisphosphate aldolase. J Biol Chem 261:11424-114